A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma

NCT04171843 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

48

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated due to lack of sufficient therapeutic effect

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

GENETIC: PBCAR269A
DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Nirogacestat

Sponsor

Precision BioSciences, Inc.